TD Asset Management’s Maze Therapeutics MAZE Stock Holding History

TD Asset Management’s Portfolio MAZE Stock Details MAZE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$662K	Buy	+22,174	New	+$581K	﹤0.01%	1152

Other funds holding MAZE

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

FWP

Falcon Wealth Planning Ontario, California $1.58B AUM 20.99% 1-Year Est. Return

State of New Jersey Common Pension Fund D Trenton, New Jersey $29.3B AUM 38.15% 1-Year Est. Return

TD Asset Management's MAZE Position: Q2 2026 in Review

TD Asset Management opened a new position in Maze Therapeutics (MAZE) in Q2 2026: 22,174 shares worth $662K. The stake represents ﹤0.01% of the portfolio and ranks #1152 among its holdings.

22 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

TD Asset Management held 22,174 shares of Maze Therapeutics worth $662K as of Q2 2026.
Maze Therapeutics was a new TD Asset Management position in Q2 2026.
Maze Therapeutics made up ﹤0.01% of TD Asset Management's portfolio in Q2 2026, its #1152 holding.
22 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.